News
We send the latest information from SMC Laboratories.
Terns Pharmaceuticals Inc. announced that initiation of patient dosing in the LIFT study, a phase 2A clinical trial of TERN-101 in development for NASH
Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in the Phase2A study (LIFT study) of TERN-101 in development for NASH. TERN-101 is FXR agonist. This compound is a non-bile acid FXR agonist unlike Intercept's FXR agonist (OCA), which was recently dropped, and is expected to have…
NIDDK's publication in Purinergic Signaling
SMC announces that NIDDK (MD) has published the results of a study using the STAMTM mouse model in Purinergic Signaling. Title: “Design and in vivo activity of A3 adenosine receptor agonist prodrugs” https://link.springer.com/article/10.1007/s11302-020-09715-0 In this paper, they report the results of a pharmacology study of a A3 adenosine receptor agonist prodrug (MRS7476) using…
Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.
Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical trial and concentrate on developing PBC therapeutics. RESOLVE-IT Phase 3 clinical trial did not show any improvement in the primary endpoint, resulting in a change in corporate strategy. Following the recent news of OCA, the drop of Elafibranor,…
Merck's publication in Cell Reports Medicine
SMC announces that Merck & Co., Inc. (NJ) has published the results of a study using STAMTM mouse model in Cell Reports Medicine. Title: “Molecular Profiling Reveals a Common Metabolic Signature of Tissue Fibrosis” In this paper, they report the results of pharmacology study of MK-8722 (AMPK activator) and MK-4074 (ACC inhibitor) using…
DURECT has published a news release regarding positive topline data from phase 1b study of DUR-928 in NASH
DURECT CORPORATION (USA) announced on May 26, 2020, that positive topline data was obtained in serum liver enzymes (ALT, AST, GGT) and liver stiffness as measured by Fibroscan in the Phase 1b for NASH patients. DUR-928 is a endogenous epigenetic regulator. The compound used the STAMTM mouse model for non-clinical studies, and data showing…
FDA rejects Intercept Pharma's drug for NASH for now
Intercept Pharmaceuticals, Inc. (USA) announced that it has received a notification from the FDA that it will not approve the application for FXAR agonist (OCA) for liver fibrosis by NASH on June 29, 2020. OCA has reported to have side efects such as itching and an increase in total cholesterol level. The announce is…
Hepion pharma has publshed a pres releaes regarding the CRV431 efficacy evaluation study for kidney fibrosis we have provied.
Hepion pharma, which is our client, has announced the results of pharmacology study using a UUO mouse model. CRV431 is a cyclophillin inhibitor. In addition to the UUO mouse model, this compound exerts its anti-fibrosis effects in other fibrosis models such as the STAMTM mouse model, and is expected for future clinical development. …
Continuum Biosciences’s publication in Journal of Medicinal Chemistry
SMC announces that Continuum Biosciences, Pty Ltd. has published the results of a study using STAM model on Journal of Medicinal Chemistry (https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00542) . Title: “6-Amino-[1,2,5]oxadiazolo[3,4-b]pyrazin-5-ol Derivatives as Efficacious Mitochondrial Uncouplers in STAM Mouse Model of Non-alcoholic Steatohepatitis”
Sabinsa Corporation’s publication in Scientific Reports
SMC announces that Sabinsa Corporation has published the results of a study using STAM model in Scientific Reports. Title: “Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice”
Juntendo University’s publication on European Radiology Experimental
SMC announces that Juntendo University has published the results of a study using STAM™ model in European Radiology Experimental. Title: “Free fatty acid-based low-impedance liver image: a characteristic appearnace in nonalcoholic steatohepatitis (NASH)” Free fatty acid-based low-impedance liver image: a characteristic appearance in nonalcoholic steatohepatitis (NASH) | European Radiology Experimental | Full Text (springeropen.com)…